Pancreatic Cancer Research

ResearcherChiba Cancer CenterNo recent work listed

Wataru Takayama

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5035502991. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: none · 2022: 4 papers

Papers 9

  1. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  2. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  3. Transcriptomic analysis reveals high ITGB1 expression as a predictor for poor prognosis of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0268630↗
  4. Machine learning with imaging features to predict the expression of ITGAV, which is a poor prognostic factor derived from transcriptome analysis in pancreatic … Co-author DOI 10.3892/ijo.2022.5350↗
  5. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. Last author DOI 10.1038/s41416-020-0997-1↗
  6. MIR1246 in body fluids as a biomarker for pancreatic cancer. Last author DOI 10.1038/s41598-020-65695-6↗
  7. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Last author DOI 10.1186/s12885-020-07698-0↗
  8. Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma. Last author DOI 10.3892/mco.2020.2047↗
  9. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Co-author DOI 10.1038/s41598-019-52486-x↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yosuke Iwatate · 5 shared papers, 2020–2022 · strength 0.58
  2. Fumitaka Ishige · 5 shared papers, 2020–2022 · strength 0.58
  3. Hidehito Arimitsu · 5 shared papers, 2020–2022 · strength 0.58
  4. Hiroki Nagase · 5 shared papers, 2020–2022 · strength 0.58
  5. Yasukuni Mori · 3 shared papers, 2020–2022 · strength 0.36
  6. Katsuhiko Uesaka · 3 shared papers, 2020–2022 · strength 0.33
  7. Hirochika Toyama · 3 shared papers, 2020–2022 · strength 0.33
  8. Soichiro Morinaga · 3 shared papers, 2020–2022 · strength 0.33
  9. Naoki Kuwayama · 2 shared papers, 2022 · strength 0.25
  10. Osamu Shimozato · 2 shared papers, 2022 · strength 0.25
  11. Takashi Uno · 2 shared papers, 2022 · strength 0.25
  12. Norihisa Takakura · 2 shared papers, 2020–2022 · strength 0.21
  13. Keishi Sugimachi · 2 shared papers, 2020–2022 · strength 0.21
  14. Atsushi Miyamoto · 2 shared papers, 2020–2022 · strength 0.21
  15. Masafumi Ikeda · 2 shared papers, 2020–2022 · strength 0.21
  16. Shinichiro Takahashi · 2 shared papers, 2020–2022 · strength 0.21
  17. Motohiro Kojima · 2 shared papers, 2020–2022 · strength 0.21
  18. Wataru Kimura · 1 shared paper, 2022 · strength 0.12
  19. Masato Nagino · 1 shared paper, 2022 · strength 0.12
  20. Tetsuo Akimoto · 1 shared paper, 2022 · strength 0.12
  21. Takehito Otsubo · 1 shared paper, 2022 · strength 0.12
  22. Satoshi Hirano · 1 shared paper, 2022 · strength 0.12
  23. Akira Fukutomi · 1 shared paper, 2022 · strength 0.12
  24. Shoji Nakamori · 1 shared paper, 2022 · strength 0.12
  25. Amane Takahashi · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.